Our top pick for
RAPT Therapeutics, Inc is a biotechnology business based in the US. RAPT Therapeutics shares (RAPT) are listed on the NASDAQ and all prices are listed in US Dollars. RAPT Therapeutics employs 68 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$13.36 - $41.86|
|50-day moving average||$21.27|
|200-day moving average||$23.58|
|Wall St. target price||$36.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.89|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing RAPT Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of RAPT Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
RAPT Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, RAPT Therapeutics shares trade at around 1x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||$5 million|
|Gross profit TTM||$5 million|
|Return on assets TTM||-32.67%|
|Return on equity TTM||-59.66%|
|Market capitalisation||$517.9 million|
TTM: trailing 12 months
There are currently 908,919 RAPT Therapeutics shares held short by investors – that's known as RAPT Therapeutics's "short interest". This figure is 0.7% up from 902,726 last month.
There are a few different ways that this level of interest in shorting RAPT Therapeutics shares can be evaluated.
RAPT Therapeutics's "short interest ratio" (SIR) is the quantity of RAPT Therapeutics shares currently shorted divided by the average quantity of RAPT Therapeutics shares traded daily (recently around 192160.46511628). RAPT Therapeutics's SIR currently stands at 4.73. In other words for every 100,000 RAPT Therapeutics shares traded daily on the market, roughly 4730 shares are currently held short.
However RAPT Therapeutics's short interest can also be evaluated against the total number of RAPT Therapeutics shares, or, against the total number of tradable RAPT Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case RAPT Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 RAPT Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0797% of the tradable shares (for every 100,000 tradable RAPT Therapeutics shares, roughly 80 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against RAPT Therapeutics.
Find out more about how you can short RAPT Therapeutics stock.
We're not expecting RAPT Therapeutics to pay a dividend over the next 12 months.
RAPT Therapeutics, Inc. , a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.